<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37641400</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>31</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1941-5923</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><PubDate><Year>2023</Year><Month>Aug</Month><Day>29</Day></PubDate></JournalIssue><Title>The American journal of case reports</Title><ISOAbbreviation>Am J Case Rep</ISOAbbreviation></Journal><ArticleTitle>Co-Presentation of Lupus Nephritis with Autoimmune Hepatitis.</ArticleTitle><Pagination><StartPage>e940478</StartPage><MedlinePgn>e940478</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.12659/AJCR.940478</ELocationID><Abstract><AbstractText>BACKGROUND Systemic lupus erythematosus (SLE) is a multiorgan immunologic disease which commonly results in systemic manifestations by involving joints, kidneys, skin, heart, hematologic cell lines, pulmonary and central nervous systems. The hepatic involvement of lupus is relatively less common, which creates diagnostic challenges, as the clinical presentations of lupus hepatitis and autoimmune hepatitis (AIH) are similar. CASE REPORT A 51-year-old woman presented for multiple joint pain that began 2 years ago. Her work-up, including kidney biopsy, was consistent with a diagnosis of class V lupus nephritis. Subsequently, within a few months, she was admitted with acute elevation of liver enzymes and high immunoglobulin IgG level, and a liver biopsy demonstrated impressive interface hepatitis with many plasma cells and lymphocytes, suggestive of chronic hepatitis with high histological activity. This case illustrates the co-presentation of lupus nephritis and AIH, which is a rare association. The patient was managed with a tapering dose of prednisone, hydroxychloroquine initially, and later with mycophenolate mofetil, with complete resolution of liver enzyme abnormalities by 4-month follow-up. CONCLUSIONS Lupus hepatitis is hepatic involvement of SLE, which should be distinguished from AIH. Accurate diagnosis is important, as management and prognosis of these immunologic conditions can differ. Although both entities share clinical and biochemical markers, the presence of anti-ribosomal P antibodies and liver histology features of predominant lymphoid infiltrates with lobular inflammation favor lupus hepatitis. A multidisciplinary approach involving rheumatologists, hepatologists, and pathologists can improve disease outcomes by properly differentiating the 2 entities and guiding the selection of appropriate immunosuppressive therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chaudhary</LastName><ForeName>Fizah S</ForeName><Initials>FS</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of Missouri, Columbia, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sureen</LastName><ForeName>Amit</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6305-9702</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, University of Missouri, Columbia, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yousaf</LastName><ForeName>Muhammad Nadeem</ForeName><Initials>MN</Initials><Identifier Source="ORCID">0000-0002-7979-8929</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, University of Missouri, Columbia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Deepthi S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Department of Pathology and Anatomical Sciences, University of Missouri, Columbia, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Siva</LastName><ForeName>Chokkalingam</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine, University of Missouri, Columbia, MO, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Case Rep</MedlineTA><NlmUniqueID>101489566</NlmUniqueID><ISSNLinking>1941-5923</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019693" MajorTopicYN="Y">Hepatitis, Autoimmune</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of interest:</b> None declared</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>29</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37641400</ArticleId><ArticleId IdType="pmc">PMC10474845</ArticleId><ArticleId IdType="doi">10.12659/AJCR.940478</ArticleId><ArticleId IdType="pii">940478</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Heneghan MA, Yeoman AD, Verma S, et al. Autoimmune hepatitis. Lancet. 2013;382(9902):1433&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">23768844</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi A, Rai T, Onizawa M, et al. Autoimmune hepatitis complicated by late-onset systemic lupus erythematosus. Hepatol Res. 2007;37(9):771&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">17506835</ArticleId></ArticleIdList></Reference><Reference><Citation>Runyon BA, LaBrecque DR, Anuras S. The spectrum of liver disease in systemic lupus erythematosus. Report of 33 histologically-proved cases and review of the literature. Am J Med. 1980;69(2):187&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">7405944</ArticleId></ArticleIdList></Reference><Reference><Citation>Adiga A, Nugent K. Lupus hepatitis and autoimmune hepatitis (lupoid hepatitis) Am J Med Sci. 2017;353(4):329&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">28317620</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaja AJ, Morshed SA, Parveen S, Nishioka M. Antibodies to single-stranded and double-stranded DNA in antinuclear antibody-positive type 1-autoimmune hepatitis. Hepatology. 1997;26(3):567&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">9303484</ArticleId></ArticleIdList></Reference><Reference><Citation>Beisel C, Weiler-Normann C, Teufel A, Lohse AW. Association of autoimmune hepatitis and systemic lupus erythematodes: A case series and review of the literature. World J Gastroenterol. 2014;20(35):12662&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4168105</ArticleId><ArticleId IdType="pubmed">25253972</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">18305268</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update on the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">33051219</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">31383717</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020;72(2):671&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">31863477</ArticleId></ArticleIdList></Reference><Reference><Citation>Czaja AJ, Carpenter HA. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993;105(6):1824&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">8253358</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandok N, Silveira MG, Lindor KD. Comparing the simplified and international autoimmune hepatitis group criteria in primary sclerosing cholangitis. Gastroenterol Hepatol (N Y) 2010;6(2):108&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2886459</ArticleId><ArticleId IdType="pubmed">20567552</ArticleId></ArticleIdList></Reference><Reference><Citation>Muratori P, Granito A, Pappas G, Muratori L. Validation of simplified diagnostic criteria for autoimmune hepatitis in Italian patients. Hepatology. 2009;49(5):1782&#x2013;83. author reply 1783.</Citation><ArticleIdList><ArticleId IdType="pubmed">19402135</ArticleId></ArticleIdList></Reference><Reference><Citation>Leggett BA. The liver in systemic lupus erythematosus. J Gastroenterol Hepatol. 1993;8(1):84&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">8439667</ArticleId></ArticleIdList></Reference><Reference><Citation>West M, Jasin HE, Medhekar S. The development of connective tissue diseases in patients with autoimmune hepatitis: A case series. Semin Arthritis Rheum. 2006;35(6):344&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">16765710</ArticleId></ArticleIdList></Reference><Reference><Citation>Lohse AW. Rolls Royce for everybody? Diagnosing liver disease by mini-laparoscopy. J Hepatol. 2011;54(3):584&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">21159402</ArticleId></ArticleIdList></Reference><Reference><Citation>Usta Y, Gurakan F, Akcoren Z, Ozen S. An overlap syndrome involving autoimmune hepatitis and systemic lupus erythematosus in childhood. World J Gastroenterol. 2007;13(19):2764&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4147132</ArticleId><ArticleId IdType="pubmed">17569152</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvarez F, Ciocca M, Ca&#xf1;ero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol. 1999;30(2):222&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">10068099</ArticleId></ArticleIdList></Reference><Reference><Citation>Salem C ME, Murr TEI. Case report and review of literature: An overlap syndrome of autoimmune hepatitis and systemic lupus erythematous. Clin Med Rev Case Rep. 2019;6(1):249&#x2013;52.</Citation></Reference><Reference><Citation>Santiago P, Schwartz I, Tamariz L, Levy C. Systematic review with meta-analysis: Mycophenolate mofetil as a second-line therapy for autoimmune hepatitis. Aliment Pharmacol Ther. 2019;49(7):830&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">30761563</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>